E Toussirot

Summary

Affiliation: CHU Jean Minjoz
Country: France

Publications

  1. ncbi Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series
    Eric Toussirot
    CIC Biotherapy 506, University Hospital St Jacques, Boulevard Fleming, 25000 Besancon, France
    Joint Bone Spine 79:457-63. 2012
  2. ncbi [Adipokines: some players of inflammation in inflammatory rheumatic diseases and systemic autoimmune diseases?]
    Eric Toussirot
    CHU hôpital Saint Jacques, Pole Recherche, centre investigation clinique biothérapie 506, 25000 Besancon, France
    Presse Med 42:13-8. 2013
  3. ncbi The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases
    Eric Toussirot
    Clinical Investigation Center CIC Biotherapy 506, St Jacques Hospital, Batiment St Joseph, Besancon, France
    Inflamm Allergy Drug Targets 11:159-68. 2012
  4. ncbi Elevated adiponectin serum levels in women with systemic autoimmune diseases
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besancon Cedex, France
    Mediators Inflamm 2010:938408. 2010
  5. ncbi Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
    Eric Toussirot
    Service de Rhumatologie, CHU hôpital Minjoz, pôle pathologies aiguës et chroniques, Transplantation, éducation Pacte, boulevard A Fleming, 25000 Besancon, France
    Joint Bone Spine 77:395-8. 2010
  6. ncbi Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Drugs Aging 27:523-31. 2010
  7. ncbi The use of TNF-alpha blocking agents in rheumatoid arthritis: an update
    Eric Toussirot
    University Hospital Jean Minjoz, Department of Rheumatology, Besancon Cedex, France
    Expert Opin Pharmacother 8:2089-107. 2007
  8. ncbi Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Boulevard Fleming, Besancon Cedex, France
    Arthritis Res Ther 11:R101. 2009
  9. ncbi Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update
    Eric Toussirot
    Rheumatology Department, Jean Minjoz Teaching Hospital, boulevard A Fleming, 25030 Besancon, France
    Joint Bone Spine 74:418-26. 2007
  10. ncbi Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Inflamm Allergy Drug Targets 9:51-9. 2010

Collaborators

Detail Information

Publications67

  1. ncbi Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series
    Eric Toussirot
    CIC Biotherapy 506, University Hospital St Jacques, Boulevard Fleming, 25000 Besancon, France
    Joint Bone Spine 79:457-63. 2012
    ..To describe cases of new onset of inflammatory bowel disease (IBD) in patients with inflammatory rheumatic disease (IRD) receiving anti-TNF-α therapy...
  2. ncbi [Adipokines: some players of inflammation in inflammatory rheumatic diseases and systemic autoimmune diseases?]
    Eric Toussirot
    CHU hôpital Saint Jacques, Pole Recherche, centre investigation clinique biothérapie 506, 25000 Besancon, France
    Presse Med 42:13-8. 2013
    ..Adiponectin is considered to be protective for cardiovascular risk. The influence of the treatments given in inflammatory rheumatic diseases and autoimmune diseases (traditional drugs and biologics) on adipokines requires to be studied...
  3. ncbi The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases
    Eric Toussirot
    Clinical Investigation Center CIC Biotherapy 506, St Jacques Hospital, Batiment St Joseph, Besancon, France
    Inflamm Allergy Drug Targets 11:159-68. 2012
    ..Targeting the IL-23/Th17 axis seems to be a relevant and realistic therapeutic approach and these new agents pave the way for additive and alternative treatments to currently available biologics in chronic inflammatory diseases...
  4. ncbi Elevated adiponectin serum levels in women with systemic autoimmune diseases
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besancon Cedex, France
    Mediators Inflamm 2010:938408. 2010
    ..However, the precise consequences of these elevated serum adiponectin levels on the metabolic syndrome development and atherosclerotic cardiovascular risk in this patient population still needs to be determined...
  5. ncbi Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
    Eric Toussirot
    Service de Rhumatologie, CHU hôpital Minjoz, pôle pathologies aiguës et chroniques, Transplantation, éducation Pacte, boulevard A Fleming, 25000 Besancon, France
    Joint Bone Spine 77:395-8. 2010
    ..In humans, the only relevant data available so far come from studies of HAT and HDAC expression in the synovial membrane of patients with rheumatoid arthritis. HDIs may hold promise for the treatment of inflammatory joint disease...
  6. ncbi Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Drugs Aging 27:523-31. 2010
    ..Thus, the clinician must be familiar with the clinical characteristics and particularities of this group of inflammatory rheumatic diseases...
  7. ncbi The use of TNF-alpha blocking agents in rheumatoid arthritis: an update
    Eric Toussirot
    University Hospital Jean Minjoz, Department of Rheumatology, Besancon Cedex, France
    Expert Opin Pharmacother 8:2089-107. 2007
    ....
  8. ncbi Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Boulevard Fleming, Besancon Cedex, France
    Arthritis Res Ther 11:R101. 2009
    ..Here, we evaluated circulating levels of sCTLA-4 as a marker of immune dysregulation in SpA. Intracellular CTLA-4 and levels of CTLA-4 transcript expression in peripheral blood lymphocytes (PBL) were also studied...
  9. ncbi Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update
    Eric Toussirot
    Rheumatology Department, Jean Minjoz Teaching Hospital, boulevard A Fleming, 25030 Besancon, France
    Joint Bone Spine 74:418-26. 2007
    ..The effect of biotherapies for RA on EBV-host relations needs to be investigated...
  10. ncbi Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Inflamm Allergy Drug Targets 9:51-9. 2010
    ..It may therefore be regarded as a relevant outcome variable in clinical trials and for the management of patients with RA in clinical practice...
  11. ncbi Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice
    Eric Toussirot
    Rheumatology Department, Besançon Hospital, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besancon, France
    Joint Bone Spine 77:142-5. 2010
    ..To report our experience with rituximab therapy in patients with rheumatoid arthritis (RA) and a history of severe or recurrent bacterial infections...
  12. ncbi Spinal cord compression complicating aseptic spondylodiscitis in ankylosing spondylitis
    E Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Clin Exp Rheumatol 27:654-7. 2009
    ....
  13. ncbi Current therapeutics for spondyloarthritis
    Eric Toussirot
    Department of Rheumatology, University Hospital, 25000 Besancon, France
    Expert Opin Pharmacother 12:2469-77. 2011
    ..International recommendations for the management of AS by the Assessment of Spondyloarthritis (ASAS) group were recently updated and discussed the respective place of each current therapeutic option in AS...
  14. ncbi Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon, Cedex, France
    Metabolism 56:1383-9. 2007
    ..Leptin production was reduced in contrast with normal levels of adiponectin. These adipokine results, together with high serum ghrelin levels, may influence the inflammatory response in AS...
  15. ncbi [TNFα blocking agents and sarcoidosis: an update]
    E Toussirot
    Service de Rhumatologie, pôle de pathologies aiguës et chroniques, Transplantation, éducation Pacte, Hopital Minjoz, CHU, 25000 Besancon, France
    Rev Med Interne 31:828-37. 2010
    ..Changes in the cytokine balance may be involved in these cases of induced sarcoidosis, which must be known by the clinician...
  16. ncbi Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases
    E Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Clin Exp Rheumatol 26:471-5. 2008
    ..Limited and various similar cases have been reported. It is generally considered that these granulomatous diseases are related to the anti-TNF-alpha agent...
  17. ncbi Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, EA 3186 Agents Pathogènes et Inflammation, IFR 133 University of Franche Comté, CIC Biotherapy 506, St Jacques Hospital, Besancon, France
    J Rheumatol 36:2421-7. 2009
    ..To describe cases of development of pulmonary nodulosis or aseptic granulomatous lung disease in patients with rheumatoid arthritis (RA) receiving anti-tumor necrosis factor-alpha (TNF-alpha) therapy...
  18. ncbi Epstein-Barr virus in autoimmune diseases
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besançon and EA 3186 Agents Pathogènes et Inflammation, University of Franche Comte, Besancon, France
    Best Pract Res Clin Rheumatol 22:883-96. 2008
    ..The influence of new and emergent treatments of these autoimmune diseases (biological therapies) on EBV load and the course of latent EBV infection requires further studies...
  19. ncbi Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis
    E Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besancon Cedex, France
    Rheumatology (Oxford) 44:120-5. 2005
    ....
  20. ncbi The association of HLA-DM genes with rheumatoid arthritis in Eastern France
    E Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Hum Immunol 61:303-8. 2000
    ..Thus, our results suggest that DMA*0103 could be an additional genetic factor for RA susceptibility in French whites...
  21. ncbi HLA DRB1* alleles in rheumatoid nodulosis: a comparative study with rheumatoid arthritis with and without nodules
    E Toussirot
    Department of Rheumatology, University Hospital J Minjoz, Besancon, France
    Rheumatol Int 17:233-6. 1998
    ..This study is restricted by the small number of tested RN patients, but the results suggest that the RA-associated alleles are poorly expressed in RN...
  22. ncbi [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies]
    Daniel Wendling
    Service de Rhumatologie, CHU Jean Minjoz, Besancon
    Presse Med 32:1517-24. 2003
    ....
  23. ncbi Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis
    E Toussirot
    Department of Rheumatology, University Hospital J Minjoz, Bd A Fleming, 25030 F Besançon, France
    Ann Rheum Dis 59:533-8. 2000
    ..This study evaluated the specific T cell response to EBV gp110 in patients with RA expressing or not the shared epitope and examined whether this immune cellular response might be related to disease activity and severity...
  24. ncbi [Hypercalcemia of double origin: association of multiple myeloma and ectopic parathyroidal adenoma]
    C Fery Blanco
    Service de Rhumatologie, CHU Jean Minjoz, Boulevard Fleming, 25000 Besançon Cedex, France
    Rev Med Interne 28:504-6. 2007
    ..Multiple myeloma and primary hyperparathyroidism are two causes of hypercalcemia. This association has already been described to be not casual, despite their link is still unknown...
  25. ncbi Bone density, ultrasound measurements and body composition in early ankylosing spondylitis
    E Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd A. Fleming, , France
    Rheumatology (Oxford) 40:882-8. 2001
    ..As it is thought that QUS provides information about qualitative properties of bone, the normal results of QUS values in our patient series argue against modifications in AS bone micro-architecture...
  26. ncbi Anti-TNF-alpha therapy in ankylosing spondylitis
    Daniel Wendling
    University Teaching Hospital Minjoz, Department of Rheumatology, Boulevard Fleming, F 25030 Besancon, France
    Expert Opin Pharmacother 5:1497-507. 2004
    ..Despite these concerns, Anti-TNF represents a major therapeutic advancement in the treatment of AS...
  27. ncbi High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies
    M Drouart
    Department of Rheumatology, University Hospital Jean Minjoz, , France
    Clin Exp Immunol 132:158-62. 2003
    ..These results suggest that VEGF and therefore angiogenesis may play a role in SpA pathogenesis and may serve as a disease activity marker in SpAs...
  28. ncbi Current guidelines for the drug treatment of ankylosing spondylitis
    E Toussirot
    Department of Rheumatology, University Hospital J Minjoz, Besancon, France
    Drugs 56:225-40. 1998
    ..In parallel with pharmacotherapy, these procedures are of great importance in reducing stiffness and spinal ankylosis, and thus improve the patient's quality of life...
  29. ncbi [The immunogenetics of ankylosing spondylitis]
    E Toussirot
    Service de Rhumatologie, CHU Jean Minjoz, Boulevard Fleming, 25030 Besancon Cedex, France
    Rev Med Interne 27:762-71. 2006
    ..The original molecular structures of HLA-B27 are certainly involved in this complex physiopathology, but their direct influence on the disease remains to be precised...
  30. ncbi Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease
    Daniel Wendling
    Service de Rhumatologie, CHU Minjoz et Université de Franche Comté, 25030 Besancon, France
    Joint Bone Spine 75:540-3. 2008
    ..To assess the rate of occurrence and outcomes of herpes zoster in patients taking TNFalpha antagonists...
  31. ncbi Ankylosing spondylitis and Sweet's syndrome
    Daniel Wendling
    Department of Rheumatology, University of Franche Comte, University Teaching Hospital Minjoz, 25030 Besancon, France
    Clin Rheumatol 27:S27-8. 2008
    ..Skin involvement in AS is dominated by psoriasis-type lesions. The occurrence of Sweet's syndrome is seldom reported in this condition...
  32. ncbi Acute pseudogout after pamidronate infusion
    Daniel Wendling
    Department of Rheumatology, University Teaching Hospital Minjoz, EA 3186, University of Franche Comte, Boulevard Fleming, Besancon, France
    Clin Rheumatol 27:1205-6. 2008
    ..Diagnosis was confirmed by synovial fluid analysis and was associated with hypocalcemia. Only a few cases are reported in the literature. The mechanism of this potential side effect remains speculative...
  33. ncbi Vertebral osteitis adjacent to kyphoplasty
    Daniel Wendling
    Service de Rhumatologie, CHU Minjoz, 25030 Besancon, France
    Joint Bone Spine 77:67-9. 2010
    ..Few cases of osteitis adjacent to kyphoplasty have been reported. The underlying pathophysiology may involve changes in vertebral loading and cement leakage into the intervertebral disk...
  34. ncbi Parsonage-Turner syndrome revealing Lyme borreliosis
    Daniel Wendling
    Service de Rhumatologie, CHU Jean Minjoz, et EA 3186 Agents Pathogènes et Inflammation Université de Franche Comté, Boulevard Fleming, 25030 Besancon, France
    Joint Bone Spine 76:202-4. 2009
    ..Parsonage-Turner syndrome should be added to the list of manifestations of neuroborreliosis. Serological tests for Lyme disease should be performed routinely in patients with Parsonage-Turner syndrome...
  35. ncbi Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy
    Daniel Wendling
    Service de Rhumatologie, CHU Minjoz, 25030 Besancon, France
    Joint Bone Spine 76:308-11. 2009
    ..In patients on antiviral therapy, viral load monitoring should be continued, given the risk of escape phenomenon after several years...
  36. ncbi Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies
    Eric Toussirot
    University Hospital Jean Minjoz Bd Fleming, Department of Rheumatology, F 25030 Besancon, Cedex, France
    Expert Opin Pharmacother 6:35-43. 2005
    ..Further studies are required to confirm these preliminary data and to better determine the optimal regimen (dosage and rhythm) of administration...
  37. ncbi Adult hypophosphatasia. Current aspects
    D Wendling
    Rheumatology Department, CHU Jean Minjoz, , France
    Joint Bone Spine 68:120-4. 2001
    ..Several mutations of the alkaline phosphatase gene have been identified. The genotype is correlated with the phenotype: some mutations are associated with milder forms and others with more severe forms of the disease...
  38. ncbi Therapeutic advances in ankylosing spondylitis
    E Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, boulevard A Fleming, F 25030 Besancon, France
    Expert Opin Investig Drugs 10:21-9. 2001
    ..In addition, the long-term use (efficacy and tolerability) of these two agents deserves attention...
  39. ncbi [Anti TNF-alpha treatment of a refractory polymyositis]
    D Wendling
    Service de Rhumatologie, CHU Jean Minjoz, Boulevard Fleming, 25030 Besancon Cedex, France
    Rev Med Interne 28:194-5. 2007
    ..Anti TNF-alpha agents may represent a possibility of treatment in cases of refractory polymyositis...
  40. ncbi Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon Cedex, France
    Autoimmunity 39:299-306. 2006
    ..Our results suggest that OM-89 has immunomodulatory properties by inducing changes in PBMC cytokines release suggestive of an induced Tr1 response to OM-89...
  41. ncbi Aseptic discitis in patients with ankylosing spondylitis: a retrospective study of 14 cases
    Sandrine Langlois
    Service de Rhumatologie, , CHU, Boulevard Fleming, , France
    Joint Bone Spine 72:248-53. 2005
    ..Discitis usually occurs at an advanced stage of AS under the form of an erosive condition related to both mechanical factors and osteoporosis. Inaugural or early discitis can occur, however, as a result of the inflammatory process...
  42. ncbi Recent progress in ankylosing spondylitis treatment
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon, France
    Expert Opin Pharmacother 4:1-12. 2003
    ....
  43. ncbi Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon Cedex, France
    Curr Opin Rheumatol 19:340-5. 2007
    ..Thus, bisphosphonates may be reasonably used as a therapeutic agent in ankylosing spondylitis...
  44. ncbi Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice
    Daniel Wendling
    Rheumatology Department, Minjoz Teaching Hospital, CHU Minjoz, 25030 Besancon, France
    Joint Bone Spine 72:309-12. 2005
    ..Infliximab is a major breakthrough in the management of rheumatoid arthritis (RA). We evaluated infliximab continuation rates and reasons for discontinuation in patients with RA...
  45. ncbi Anterior chest wall malignancies. A review of ten cases
    E Toussirot
    Rheumatology Department, Minjoz Teaching Hospital, Besancon, France
    Rev Rhum Engl Ed 65:397-405. 1998
    ..To report the features of malignancies responsible for a chest wall mass and involving the sternum, the sternocostal and/or sternoclavicular joints, the chondrocostal junction and/or the adjacent soft tissues...
  46. ncbi The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Cedex, France
    Expert Opin Pharmacother 5:581-94. 2004
    ....
  47. ncbi The contribution of adipose tissue and adipokines to inflammation in joint diseases
    Eric Toussirot
    Department of Rheumatology, Jean Minjoz University Hospital, Bd Fleming, F 25030 Besancon Cedex, France
    Curr Med Chem 14:1095-100. 2007
    ..Thus, fat tissue is an active organ whose products contribute to inflammatory and degenerative processes underlying common joint diseases...
  48. ncbi Adiponectin in autoimmune diseases
    E Toussirot
    Clinical Investigation Center CIC Biotherapy 506, University Hospital of Besancon, 25000 Besancon, France
    Curr Med Chem 19:5474-80. 2012
    ..Thus, the relative contribution of each adiponectin isoform to the inflammatory response and joint and/or tissue damage requires further study...
  49. ncbi Marked elevation of serum N-acetyl-beta-D-hexosaminidase activity in rheumatoid rheumatoid arthritis
    F Berenbaum
    Department of Rheumatology, Hopital Saint Antoine, Paris, France
    Clin Exp Rheumatol 18:63-6. 2000
    ..To study N-acetyl-beta-D-hexosaminidase (NAHase) activity in the sera of rheumatoid arthritis (RA) patients and to determine its source...
  50. ncbi TAP1 and TAP2 gene polymorphism in rheumatoid arthritis in a population in eastern France
    S L Zhang
    Blood Transfusion Center Bourgogne Franche Comté, UPRES EA 2284, Besancon, France
    Eur J Immunogenet 29:241-9. 2002
    ..This association was found to be weak and did not seem to be a predictor for the severity of the disease...
  51. ncbi Fibromyalgia developed after administration of gonadotrophin-releasing hormone analogue
    E Toussirot
    University Hospital Jean Minjoz, Besancon, France
    Clin Rheumatol 20:150-2. 2001
    ..The gonadotrophin-releasing hormone analogue treatment probably induced disturbances in the neuroendocrine system and the secretion of neurotransmitters, and may be suspected to be the cause of this case of fibromyalgia...
  52. ncbi DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis
    Fabrice Michel
    Rheumatology Department, CHU Jean Minjoz Teaching Hospital, Boulevard Fleming, , cedex 25030, France
    Joint Bone Spine 72:82-5. 2005
    ..Serological tests for HHV6 should be performed routinely in patients with suspected DRESS syndrome, although uncertainty persists about the link between HHV6 infection and DRESS syndrome...
  53. ncbi Giant intraosseous cyst-like lesions in rheumatoid arthritis report of a case
    Anne Lohse
    Rheumatology Department, CHU Jean-Minjoz, , France
    Joint Bone Spine 70:67-70. 2003
    ..quot;Synovial cyst" is a misnomer for these giant lesions, which are geodes rather than cysts. Despite their low incidence, these lesions deserve attention because they raise diagnostic and therapeutic problems...
  54. ncbi Imaging study scores for ankylosing spondylitis
    Daniel Wendling
    Rheumatology Department, Jean Minjoz Teaching Hospital, Boulevard Fleming, 25030 Besancon Cedex, France
    Joint Bone Spine 73:655-60. 2006
    ..MRI has proved sensitive to change in patients taking TNF antagonists. An outcome measures in rheumatology clinical trials (OMERACT) task force is working on standardizing MRI scores for the spine and sacroiliac joints...
  55. ncbi Yellow nail syndrome associated with thiol compound therapy for rheumatoid arthritis. Two case reports
    Gaelle Lehuede
    Rheumatology Department, CHU Jean Minjoz, Besancon, France
    Joint Bone Spine 69:406-8. 2002
    ..We report two new cases of yellow nail syndrome in patents receiving thiol compound therapy for rheumatoid arthritis. Eight similar cases have been reported since 1979, suggesting a possible causative effect of this class of drugs...
  56. ncbi Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F 25030 Besancon Cedex, France
    Recent Pat Inflamm Allergy Drug Discov 1:39-47. 2007
    ....
  57. ncbi Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren's syndrome and hepatitis C virus infection
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    J Rheumatol 29:2382-5. 2002
    ..To determine whether hepatitis C virus (HCV) RNA could be detected in the salivary glands of patients with both a diagnosis of Sjögren's syndrome (SS) and HCV infection...
  58. ncbi Pedicle stress fracture: an unusual complication of pycnodysostosis
    Paul Ornetti
    Department of Rheumatology, University Teaching Hospital, Franche Comte University, 25030, Besancon, France
    Clin Rheumatol 27:385-7. 2008
    ..The dramatic improvement achieved by calcitonin therapy might be related to osteoclastic dysfunction in pycnodysostosis caused by a deficiency of cathepsin K, a cystein protease involved in bone matrix remodelling...
  59. ncbi Avascular necrosis of the hallucal sesamoids update with reference to two case-reports
    Eric Toussirot
    Rheumatology Department, CHU Hôpital Jean Minjoz, Boulevard Fleming, 25030 Besancon, Cedex, France
    Joint Bone Spine 70:307-9. 2003
    ..The suggestive roentgenographic and MRI findings rule out the other painful conditions of the sesamoid bone. The features are reviewed and the treatment options discussed...
  60. ncbi Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options
    Eric Toussirot
    Department of Rheumatology, University Hospital Jean Minjoz, Besancon, France
    Drugs Aging 22:451-69. 2005
    ....
  61. ncbi Herpes zoster sciatica with paresis preceding the skin lesions. Three case-reports
    Daniel Wendling
    Rheumatology Department, Jean Minjoz Teaching Hospital, Boulevard Fleming, 25030 Besancon, France
    Joint Bone Spine 71:588-91. 2004
    ..Early diagnosis and treatment may improve the prognosis. Tests for antibodies or viral DNA in cerebrospinal fluid can be helpful, although negative results do not rule out the diagnosis...
  62. ncbi Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis
    Daniel Wendling
    Joint Bone Spine 73:215-6. 2006
  63. ncbi Bacillus calmette-guérin vaccination in a patient treated with infliximab
    Eric Toussirot
    J Rheumatol 32:2500-1. 2005
  64. ncbi Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance
    Eric Toussirot
    J Rheumatol 33:1027-8. 2006
  65. ncbi Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis
    Sandrine Guis
    INSERM UMR 639 and Assistance Publique Hôpitaux de Paris, Hopital de la Conception, Marseille, France
    Arthritis Rheum 57:1426-30. 2007
    ..To determine whether the -308 A/G tumor necrosis factor alpha (TNFalpha) gene polymorphism can predict the outcome of etanercept therapy in 86 patients with rheumatoid arthritis (RA), as already observed in patients treated with infliximab...
  66. ncbi Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis
    Daniel Wendling
    Joint Bone Spine 75:510-1. 2008
  67. ncbi Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?
    Daniel Wendling
    J Rheumatol 34:1647-9. 2007